- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Zepbound
Recent news which mentions Zepbound
From Benzinga
From Benzinga
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
May 12, 2025
From Benzinga
From Benzinga
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
March 06, 2025
From Benzinga
From Benzinga
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
December 20, 2024
From Benzinga
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
December 10, 2024
Tickers
LLY
From Benzinga
From Benzinga
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
November 21, 2024
From Benzinga
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
October 30, 2024
From Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
October 22, 2024
From Benzinga
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
October 01, 2024
From Benzinga
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
September 25, 2024
Tickers
LLY
From Benzinga
Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound
September 12, 2024
From Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
From Benzinga
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
August 09, 2024
From Benzinga
What's Going On With HIMS Shares Today?
August 01, 2024
From Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
From Benzinga
Ben & Jerry's Co-Founders Not Worried About Ozempic's Impact On Ice Cream Business: Here's Why
June 27, 2024
From Benzinga
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
June 20, 2024
From Benzinga
From Benzinga
From Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
May 21, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.